Decoy Therapeutics Inc.

For the period ended Jun 30, 2026. Filed Aug 12, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 12, 2026

DCOY$1.10-2.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

	June 30, 2026	December 31, 2025
	(Unaudited)	Audited
Assets
Current assets:
Cash, cash equivalents, and restricted cash	$8,289,108	$10,709,937
Prepaid expenses and other current assets	284,200	275,223
Total current assets	8,573,308	10,985,160
Property and equipment, net	399,077	40,559
Other assets	28,775	30,988
Total assets	$9,001,160	$11,056,707
Liabilities, convertible preferred stock and stockholders' equity
Current liabilities:
Accounts payable	$1,326,782	$940,586
Accrued expenses and other current liabilities	215,697	861,748
Deferred revenue	2,997,952	3,225,581
Due to related party	139,823	139,823
Total current liabilities	4,680,254	5,167,738
Total liabilities	$4,680,254	$5,167,738
Commitments and contingencies (Note 5)
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; 1,674 and 1,674 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	-	-
Common stock, $0.0001 par value; 100,000,000 shares authorized; 531,968 and 531,968 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	53	53
Additional paid-in capital	103,361,379	100,331,014
Accumulated deficit	(99,040,526)	(94,442,098)
Total stockholders' equity	4,320,906	5,888,969
Total liabilities and stockholders' equity	$9,001,160	$11,056,707

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.